Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

Conditions

• Neovascular Glaucoma

Eligibility Criteria

Sex

ALL

Age

21 Years - 90 Years

Healthy Volunteers

Not accepted

Interventions

• Aflibercept — DRUG
  Details covered in arm description

Study Details

This 52 week study will assess the use of intravitreal aflibercept injections in patients with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation. The investigators hypothesize that the neovascularization of the iris and angle present in neovascular glaucoma will resolve more quickly in eye treated with intravitreal aflibercept injection alone and result in increased comfort and preservation of visual field as compared to current standard of care utilizing pan-retinal photocoagulation. The advantages to intravitreal aflibercept injection use could include resolution of NVI/NVA (neovascularization of the iris/neovascularization of the angle) leading to quicker pain relief and quicker lowering of IOP (intraocular pressure).

Key Dates

Start date

Jan 31, 2013

Status verified

Feb 2022

Primary completion

Oct 31, 2015

Completion

Oct 31, 2015

Study Design

Enrollment

7 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Aflibercept with Laser
  A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks
• Experimental: Aflibercept
  2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.

Primary Outcome Measure

Incidence of Adverse Events [ Time Frame: 2 year ]

Locations (1)

Find similar trials in Aurora, CO